AGN 209323

Drug Profile

AGN 209323

Alternative Names: AGN-0001; AGN-001; AGN-209323; EHT-0001; EHT-001; EHT/AGN-0001

Latest Information Update: 05 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergan; ExonHit Therapeutics
  • Developer Bristol-Myers Squibb
  • Class Analgesics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 06 Feb 2013 Bristol-Myers Squibb returns the AGN 209323 programme to Allergan and Diaxonhit
  • 06 Feb 2013 Discontinued - Phase-II for Neuropathic pain in USA (PO)
  • 19 Dec 2012 ExonHit Therapeutics has merged with InGen Biosciences to form Diaxonhit
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top